1Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl, 1998,12:147-158.
2Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.Proc Natl Acad Sci USA, 2001,98:136-141.
3Majewski M, Korecka M, Joergensen J, et al. Immunosuppressire TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation, 2003, 75:1710-1717.
4Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat Med,2002, 8:128-135.
5Luan FL, Ding R, Sharma VK, et al. Raparaycin is an effective inhibitor of human renal cancer metastasis. Kidney Int, 2003,63:917-926.
6Koehl G, Guba M, Seeliger H, et al. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation.Transplant Proc, 2003,35:2135-2136.
7Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation ,2002, 73:1565-1572.
8Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamyein. Nature ,1994, 372:570-573.
9Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc, 2003, 35: 25-34.
1Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation, 2004, 77:760-762.
2Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res,2003, 63:4472-4480.
3Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene,2003, 22 : 9282-9287.
4Schumacher G, Oidtmann M, Bahra M, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc, 2002, 34:1392-1393.
5Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int, 2003,63 : 917-926.
6Koehl G, Guba M, Seeliger H, et al. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation.Transplant Proc, 2003, 35:2135-2136.
2Dharnidharka VR,Tejani AH,Ho PL,et al.Post-transplant lymphoproliferative disorder in the United States:young Caucasian males are at highest risk.Am J Transplant,2002,2(10):993-998.
3Caillard S,Lelong C,Pessione F,et al.Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults:report of 230 cases from the French Registry.Am J Transplant,2006,6(11):2735-2742.
4Ghobrial IM,Habermann TM,Macon WR,et al.Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients;are they two different diseases? Transplantation,2005,79(2):244-247.
5A predictive model for aggressive non-Hodgkin's lymphoma.The International Non-Hodgkin's Lymphoma Prognostic Factors Project.N Engl J Med,1993,329(14):987-994.
6Dharnidharka VR,Sullivan EK,Stablein DM,et al.Risk factors for posttransplant lymphoproliferative disorder (PTLD)in pediatric kidney transplantation:a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).Transplantation,2001,71(8):1065-1068.
7Funch DP,Brady J,Ko HH,et al.Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients.Recent Results Cancer Res,2002,159:81-88.
8Guba M,Graeb C,Jauch KW,et al.Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation.Transplantation,2004,77(12):1777-1782.
9Wimmer CD,Rentsch M,Crispin A,et al.The janus face of immunosuppression-de novo malignancy after renal transplantation:the experience of the Transplantation Center Munich.Kidney Int,2007,71(12):1271-1278.
10Tsai DE,Hardy CL,Tomaszewski JE,et al.Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder:analysis of prognostic variables and long-term follow-up of 42 adult patients.Transplantation,2001,71(8):1076-1088.
